ER+ / HER2- Advanced Breast Cancer
8 clinical trials · Condition
◉ Watch ER+ / HER2- Advanced Breast Cancer
| Record | Firm | Date |
|---|---|---|
| A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer (NCT05103826) | Jiangsu HengRui Medicine Co., Ltd. | 2021-10-25 |
| A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer (NCT04541433) | AstraZeneca | 2020-09-29 |
| Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (NCT03616587) | AstraZeneca | 2018-10-11 |
| SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer (NCT03596658) | Jiangsu HengRui Medicine Co., Ltd. | 2018-07-25 |
| AZD9496 First Time in Patients Ascending Dose Study (NCT02248090) | AstraZeneca | 2014-10-22 |
Track ER+ / HER2- Advanced Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.